GLP-1 receptor agonists ‘reduce kidney failure and deaths’: meta-analysis
Commenting on the study, Associate Professor Neale Cohen said it was an important step forward for the drug class.
GLP-1 receptor agonists offer significant renal protection as well as cardiovascular benefits, a meta-analysis shows.
Australian-led research has found that patients taking the drugs have a lower risk of kidney failure, heart failure and all-cause death, regardless of their diabetes status.
